Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Thursday, July 10, 2025
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Hims & Hers offers generic semaglutide as Novo Nordisk patent lapses

July 9, 2025
in News
Reading Time: 4 mins read
A A
Hims & Hers offers generic semaglutide as Novo Nordisk patent lapses
0
SHARES
ShareShareShareShareShare

READ ALSO

Samsung launches Galaxy Z Fold 7, Flip 7 and Flip 7 FE foldable phones

Trump tariffs on cars, copper, aluminum could hit hard

Hims & Hers offers generic semaglutide as Novo Nordisk patent lapses

Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January.

“Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,” said Andrew Dudum, co-founder and CEO of Hims & Hers, in a press release. “As generic semaglutide becomes available for the first time globally, we’re focused on making it truly accessible, by combining affordability with trusted, personalized care at scale.” 

Hims, a telehealth platform, joins a growing list of drugmakers that are looking to cash in on Novo Nordisk’s lapsed patent on its GLP-1s. It’s the first time the company will be operating in Canada.

Generics are essentially copies of a brand-name drug, like Ozempic or Wegovy, that deliver the same efficacy, follow the same safety standards and are allowed once a patent expires. These drugs are different from compounded versions of medications, which are personalized treatments that are changed in form or provided in different dosing levels than commercially available doses.

The Canadian semaglutide market in 2024 generated revenue of $1.18 billion and is expected to reach $4.03 billion by 2035, according to market research firm Grand View Research.

There is still no generic version of semaglutide on the market that’s been approved by the Canadian health agency, but the approval process has begun for some in the industry.

Sandoz, a global leader in generic medicine manufacturing, told Science in early June that it filed for approval of a generic version of semaglutide with Canada’s regulatory agency Health Canada. Hims did not say in its announcement if it has started a similar application for review, but did note it’s working with “an approved partner” to ensure it’s following all local laws and regulations.

More CNBC health coverage

Some in the industry have raised concerns about Novo letting its patent lapse, and it comes as Wegovy has lost ground to Eli Lilly‘s rival treatment, Zepbound, in the U.S. But a spokesperson for the company told CNBC that all intellectual property decisions are “carefully considered,” adding that “periods of exclusivity for pharmaceutical products end as part of their normal life cycle and generic treatments may become available over time.”

This announcement by Hims follows the closing of the company’s recent acquisition of European telehealth platform Zava, which expands the health platform in Europe to Ireland, France and Germany.

This also comes after Novo Nordisk ended its collaboration with Hims & Hers, citing concerns about the company’s sales and promotion of cheaper knockoffs of its weight loss drug Wegovy.

How Novo lost its Canadian patent

According to documents filed with the Canadian Patent Database, Novo held a patent for semaglutide, but the last time the company paid the annual maintenance fee was in 2018.

Novo Nordisk’s lawyers requested a refund for the paid 2017 maintenance fee of $250 Canadian dollars ($185) because the company wanted more time to see if it wanted to pay it, according to letters included in the documents.

Two years later, the office sent a letter saying the fee, which now included a late charge bringing the total to CA$450, was not received by the prescribed due date.

Novo Nordisk had a one-year grace period to pay, but never did, and so its patent lapsed in Canada. It lapsed in 2020 when the fee was not received, but it doesn’t expire until January.

Canadian authorities confirmed in their correspondence that “once a patent has lapsed it cannot be revived.”

“Making affordable, holistic obesity treatment accessible has the potential to help strengthen the local healthcare system and unlock the potential for millions of Canadians to live healthier, more fulfilling lives,” said David Meinertz, general manager of the international business at Hims & Hers.

Don’t miss these insights from CNBC PRO

Credit: Source link

ShareTweetSendSharePin
Previous Post

$100,000+ to install elevators — these six-figure trade jobs don’t require college degrees

Next Post

Aryna Sabalenka has awkward Wimbledon moment with TV presenter

Related Posts

Samsung launches Galaxy Z Fold 7, Flip 7 and Flip 7 FE foldable phones
News

Samsung launches Galaxy Z Fold 7, Flip 7 and Flip 7 FE foldable phones

July 9, 2025
Trump tariffs on cars, copper, aluminum could hit hard
News

Trump tariffs on cars, copper, aluminum could hit hard

July 9, 2025
U.S. copper price spike could have severe economic consequences
News

U.S. copper price spike could have severe economic consequences

July 9, 2025
He pays 0 in rent for a luxury condo in Thailand
News

He pays $460 in rent for a luxury condo in Thailand

July 9, 2025
A new crisis looms over Britain’s troubled rail system: UK Exchange newsletter
News

A new crisis looms over Britain’s troubled rail system: UK Exchange newsletter

July 9, 2025
China’s producer prices see worst drop in nearly two years
News

China’s producer prices see worst drop in nearly two years

July 9, 2025
Next Post
Aryna Sabalenka has awkward Wimbledon moment with TV presenter

Aryna Sabalenka has awkward Wimbledon moment with TV presenter

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

ESPN insider ‘would not rule out’ Suns keeping Kevin Durant

ESPN insider ‘would not rule out’ Suns keeping Kevin Durant

June 18, 2025
The one that happened while the Waymos burned

The one that happened while the Waymos burned

June 10, 2025
Goldman Sachs wants students to stop using ChatGPT in job interviews with the bank

Goldman Sachs wants students to stop using ChatGPT in job interviews with the bank

June 12, 2025
The best drone for 2025

The best drone for 2025

June 20, 2025
Mets send Luisangel Acuna to minors as Mark Vientos nears return

Mets send Luisangel Acuna to minors as Mark Vientos nears return

June 23, 2025
What Southeast Asia’s largest companies say about a region in flux

What Southeast Asia’s largest companies say about a region in flux

June 17, 2025
The two Luis Ortiz pitches that led to MLB’s gambling investigation

The two Luis Ortiz pitches that led to MLB’s gambling investigation

July 4, 2025

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • The best Prime Day SSD and external hard drive deals on Samsung, Crucial and more
  • Apple’s AI efforts ‘have struck midnight’ and the only way it can stop getting further behind is acquiring Perplexity, analyst Dan Ives says
  • Deion Sanders gets feisty over health questions at Big 12 media days
  • Prime Day deals discount the Amazon Smart Plug down to only $13

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In